drugset / Trial / NCT06427980
Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A prospective, randomised, double-blind, placebo-controlled, multicentre trial was designed to compare the the incidence of hematoma progression requiring operation or hematoma recurrence requiring re-operation and improves clinical outcomes at 24 weeks in patients with CSDH of treatment in the HXLS and placebo groups.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2025-12-01
- Completion
- 2026-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HuoXue LiShui | Unknown | 28.5 g | Oral |
Indications
No indication recorded.